Spain Cell And Gene Therapy Manufacturing Market Size & Outlook
Global Market
Related Markets
Spain cell and gene therapy manufacturing market highlights
- The Spain cell and gene therapy manufacturing market generated a revenue of USD 220.4 million in 2022 and is expected to reach USD 1,431.1 million by 2030.
- The Spain market is expected to grow at a CAGR of 26.3% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
| Market revenue in 2022 | USD 220.4 million |
| Market revenue in 2030 | USD 1,431.1 million |
| Growth rate | 26.3% (CAGR from 2023 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Spain accounted for 3.0% of the global cell and gene therapy manufacturing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, France cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,354.3 million by 2030.
Spain is gaining reputation in cell and gene therapy research due to expansion of major players within the country. For instance, in July 2021, Pfizer announced that they will be setting up a biotechnology plant focusing on distribution of genetic therapies across Europe.
This initiative was taken was specifically to advance treatment options for rare genetic diseases. With growing demand for advanced therapy products in the country, several companies and clinics are entering the Spanish market.
For instance, in October 2019, VIRALGEN opened a new manufacturing plant fore gene therapy in the country. This plant is expected to be one of the most modern in Europe. VIRALGEN is a leading manufacturing partner in Spain, and in September 2020, the company signed a production agreement with CombiGene AB for manufacturing of CG01—a gene therapy product for the treatment of drug-resistant focal epilepsy.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Hitachi Ltd | View profile | 322,525 | 6-6, Marunouchi 1-chome, Chiyoda-ku, Tokyo, Japan, 100-8280 | www.hitachi.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
Spain Cell And Gene Therapy Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell Therapy was the largest segment with a revenue share of 63.61% in 2022.
Horizon Databook has segmented the Spain cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Spain is gaining reputation in cell and gene therapy research due to expansion of major players within the country. For instance, in July 2021, Pfizer announced that they will be setting up a biotechnology plant focusing on distribution of genetic therapies across Europe.
This initiative was taken was specifically to advance treatment options for rare genetic diseases. With growing demand for advanced therapy products in the country, several companies and clinics are entering the Spanish market.
For instance, in October 2019, VIRALGEN opened a new manufacturing plant fore gene therapy in the country. This plant is expected to be one of the most modern in Europe. VIRALGEN is a leading manufacturing partner in Spain, and in September 2020, the company signed a production agreement with CombiGene AB for manufacturing of CG01—a gene therapy product for the treatment of drug-resistant focal epilepsy.
- Spain Cell And Gene Therapy Manufacturing Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Gene Therapy
- Cell Therapy
- Spain Cell And Gene Therapy Manufacturing Market Scale Outlook (Revenue, USD Million , 2018-2030)
- Pre-commercial/ R&D Scale
- Commercial Scale
- Spain Cell And Gene Therapy Manufacturing Market Mode Outlook (Revenue, USD Million , 2018-2030)
- Contract manufacturing
- In house manufacturing
- Spain Cell And Gene Therapy Manufacturing Market Workflow Outlook (Revenue, USD Million , 2018-2030)
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical & Quality Testing
- Raw Material Testing
- Vector Production
- Others
- Spain Cell And Gene Therapy Manufacturing Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Malignancies
- Musculoskeletal therapies
- Autoimmune disorders
- Dermatology
- Large B-Cell Lymphoma
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Cell And Gene Therapy Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy Manufacturing Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain Cell And Gene Therapy Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Spain Cell And Gene Therapy Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Spain Cell And Gene Therapy Manufacturing Market, 2018-2030 (US$M)
Spain cell and gene therapy manufacturing market statistics, by therapy type, 2018-2030 (US$M)
